ASTRAZENECA PLC reports

6-K File 001-11960

UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL

Filing date

17 Aug 2026

Reporting date

17 Aug 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG

Filing date

17 Aug 2026

Reporting date

17 Aug 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date

03 Aug 2026

Reporting date

03 Aug 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date

03 Aug 2026

Reporting date

03 Aug 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DATROWAY APPROVED IN EU FOR TNBC

Filing date

31 Jul 2026

Reporting date

31 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

FORM 6-K

Filing date

27 Jul 2026

Reporting date

30 Jun 2026

SEC evidence

Open document Open filing Open XBRL

Next action

Verify source filing

6-K File 001-11960

UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA

Filing date

27 Jul 2026

Reporting date

27 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS

Filing date

27 Jul 2026

Reporting date

27 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER

Filing date

23 Jul 2026

Reporting date

23 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR

Filing date

14 Jul 2026

Reporting date

14 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL

Filing date

09 Jul 2026

Reporting date

09 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date

01 Jul 2026

Reporting date

01 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date

01 Jul 2026

Reporting date

01 Jul 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS

Filing date

29 Jun 2026

Reporting date

29 Jun 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC

Filing date

29 Jun 2026

Reporting date

29 Jun 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TRUQAP APPROVED IN US FOR PROSTATE CANCER

Filing date

15 Jun 2026

Reporting date

15 Jun 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date

01 Jun 2026

Reporting date

01 Jun 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date

01 Jun 2026

Reporting date

01 Jun 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER

Filing date

29 May 2026

Reporting date

29 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

US FDA DECISION DATE ON CAMIZESTRANT EXTENDED

Filing date

27 May 2026

Reporting date

27 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC

Filing date

26 May 2026

Reporting date

26 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS

Filing date

26 May 2026

Reporting date

26 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU

Filing date

26 May 2026

Reporting date

26 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date

18 May 2026

Reporting date

18 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

BAXFENDY APPROVED IN THE US FOR HYPERTENSION

Filing date

18 May 2026

Reporting date

18 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing